Strategies for the use of nonstatin therapies

QR Code

Strategies for the use of nonstatin therapies

Purpose of review: Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in particular, high levels of low-density lipoprotein cholesterol (LDL-C) have been associated to a higher cardiovascular risk. Reducing LDL-C levels decreases the risk of coronary heart disease (CHD), and th...

Full description

Bibliographic Details
Main Authors:	Pirillo, A., Norata, Giuseppe, Catapano, A.
Format:	Journal Article
Published:	Lippincott Williams & Wilkins 2017
Online Access:	http://hdl.handle.net/20.500.11937/59226

Similar Items

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

Novel concepts in HDL pharmacology
by: Remaley, A., et al.
Published: (2014)

Prevalence of classical CD14++/CD16 - But not of intermediate CD14++/CD16 + monocytes in hypoalphalipoproteinemia
by: Sala, F., et al.
Published: (2013)

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

Gene silencing approaches for the management of dyslipidaemia
by: Norata, Giuseppe, et al.
Published: (2013)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
by: Norata, Giuseppe, et al.
Published: (2013)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions
by: Ruscica, M., et al.
Published: (2017)

Long pentraxin 3: Experimental and clinical relevance in cardiovascular diseases
by: Bonacina, F., et al.
Published: (2013)

LOX-1 inhibition in ApoE KO mice using a schizophyllan-based antisense oligonucleotide therapy
by: Amati, F., et al.
Published: (2012)

MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
by: Norata, Giuseppe, et al.
Published: (2013)

Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse
by: Norata, Giuseppe, et al.
Published: (2012)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

New therapeutic principles for familial hypercholesterolemia
by: Norata, Giuseppe
Published: (2014)

Trained immunity and cardiovascular disease: Is it time for translation to humans?
by: Norata, Giuseppe
Published: (2018)

PCSK9 inhibitors and dyslipidemia: The clinical evidence
by: Norata, Giuseppe
Published: (2014)